Changes

Jump to navigation Jump to search
Line 1,924: Line 1,924:  
Total 34 diagnosed patients of apasmara fulfilling the inclusion criteria and willing to register for study were enrolled for this study for the duration of 2 months. Assessment was done before and after the study period the clinical features of epilepsy by International League against Epilepsy (ILAE), patients were screened and selected according to the diagnostic criteria and a single group study was conducted. They were administered [[nasya]] with [[shatavari]] taila for seven days and later subjected to [[shamana]] therapy by [[brahmi]] ghrita. The patients were analysed after nasya at the end of seven days and later on every consecutive 15th day, for a period of two months. Frequency of the attacks were reduced after seven days of [[nasya]]. Consequently, improvements were observed in the complaints of loss of consciousness, where 93.3% reported them before treatment and after [[nasya]] it was found to be just 3.3% of the patient and later after the [[shamana]] treatment, it was found to have reduced in 76% of the patient. Convulsive movements were reported by 96% of the patient, which at the end of total therapy was found to reduce to 16.7%. Fall, epileptic cry, frothing from mouth and chattering of teeth were significantly (p < 0.001) reduced by the end of follow up period of 2 months. Similar observations were made in case of duration and severity of attacks. Epilepsy (apasmara) is an extensively researched disease and its management has just reached a stage where only seizures can be controlled. Some difficulties arise, in terms of the route of drug administration during the active state of convulsion where the conventional routes are difficult to access or inaccessible. Hence in this study, an easier route of administration i.e., nasal route was explored, for providing management with better outcome, for epilepsy. <ref>Sharmitesh R Tripathi, Savitha HP, Suhas Kumar Shetty. Efficacy of Shatavari taila Nasya and Brahmi gritha in the management of Apasmara. J Pharm Sci Innov. 2016;5(6), 181-18.</ref>
 
Total 34 diagnosed patients of apasmara fulfilling the inclusion criteria and willing to register for study were enrolled for this study for the duration of 2 months. Assessment was done before and after the study period the clinical features of epilepsy by International League against Epilepsy (ILAE), patients were screened and selected according to the diagnostic criteria and a single group study was conducted. They were administered [[nasya]] with [[shatavari]] taila for seven days and later subjected to [[shamana]] therapy by [[brahmi]] ghrita. The patients were analysed after nasya at the end of seven days and later on every consecutive 15th day, for a period of two months. Frequency of the attacks were reduced after seven days of [[nasya]]. Consequently, improvements were observed in the complaints of loss of consciousness, where 93.3% reported them before treatment and after [[nasya]] it was found to be just 3.3% of the patient and later after the [[shamana]] treatment, it was found to have reduced in 76% of the patient. Convulsive movements were reported by 96% of the patient, which at the end of total therapy was found to reduce to 16.7%. Fall, epileptic cry, frothing from mouth and chattering of teeth were significantly (p < 0.001) reduced by the end of follow up period of 2 months. Similar observations were made in case of duration and severity of attacks. Epilepsy (apasmara) is an extensively researched disease and its management has just reached a stage where only seizures can be controlled. Some difficulties arise, in terms of the route of drug administration during the active state of convulsion where the conventional routes are difficult to access or inaccessible. Hence in this study, an easier route of administration i.e., nasal route was explored, for providing management with better outcome, for epilepsy. <ref>Sharmitesh R Tripathi, Savitha HP, Suhas Kumar Shetty. Efficacy of Shatavari taila Nasya and Brahmi gritha in the management of Apasmara. J Pharm Sci Innov. 2016;5(6), 181-18.</ref>
    +
=== Effect of Brahmi Ghrita ===
 +
 +
In a clinical study on depression, Brahmi ghrita has resulted in moderate improvement for 40% patients of depression and mild improvement for 55% patients, which is statistically significant at 1% level as compared to placebo.<ref>Deole, Yogesh S1,; Chandola, HM2. A Clinical Study on Effect of Brahmi Ghrita on Depression. AYU (An international quarterly journal of research in Ayurveda) 29(4):p 207-214, Oct–Dec 2008.</ref> In experimental animals, Brahmi ghrita showed mild hyperactivity in gross behaviour and dose dependent mild anxiolytic effect in open field behaviour and elevated plus maze test. Dose dependent variation in effect of Brahmi ghrita is observed in behaviour despair test, as it is mild stimulant at lower dose and depressant at higher dose. It showed significant potentiation of L-DOPA activity in comparison to water control, but the effect was insignificant in comparison to ghrita control.<ref>Deole, Yogesh S1,; Ashok, BK2; Shukla, Vinay3; Ravishankar, B4; Chandola, HM5. Psycho-Pharmacological study on Antidepressant and Anxiolytic Effect of Brahmi Ghrita. AYU (An international quarterly journal of research in Ayurveda) 29(2):p 77-83, Apr–Jun 2008.</ref>
 +
 
=== Related Chapter ===
 
=== Related Chapter ===
   −
[[Apasmara Nidana]],[[Manas]], [[Aatma]], [[Smriti]], [[Indriya]], [[Psychiatric diseases‎‎]], [[Neurological diseases]]   
+
[[Apasmara Nidana]],[[Manas]], [[Aatma]], [[Smriti]], [[Indriya]], [[Psychiatric diseases‎‎]], [[Neurological diseases]], [[Manovaha srotas]]   
    
<big>'''[[Special:ContactMe|Send us your suggestions and feedback on this page.]]'''</big>
 
<big>'''[[Special:ContactMe|Send us your suggestions and feedback on this page.]]'''</big>

Navigation menu